BR112013002096A2 - compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas - Google Patents

compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas

Info

Publication number
BR112013002096A2
BR112013002096A2 BR112013002096A BR112013002096A BR112013002096A2 BR 112013002096 A2 BR112013002096 A2 BR 112013002096A2 BR 112013002096 A BR112013002096 A BR 112013002096A BR 112013002096 A BR112013002096 A BR 112013002096A BR 112013002096 A2 BR112013002096 A2 BR 112013002096A2
Authority
BR
Brazil
Prior art keywords
glp
receptor agonist
agonist compounds
stabilized regions
stabilized
Prior art date
Application number
BR112013002096A
Other languages
English (en)
Portuguese (pt)
Inventor
SHARMA Abhinandini
J Soares Christopher
Coats Eugene
Alfaro-Lopez Josue
S Ghosh Soumitra
Original Assignee
Amylin Pharmaceuticals Inc
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Inc
Publication of BR112013002096A2 publication Critical patent/BR112013002096A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013002096A 2010-07-28 2011-07-27 compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas BR112013002096A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36852210P 2010-07-28 2010-07-28
PCT/US2011/045614 WO2012015975A2 (en) 2010-07-28 2011-07-27 Glp-1 receptor agonist compounds having stabilized regions

Publications (1)

Publication Number Publication Date
BR112013002096A2 true BR112013002096A2 (pt) 2019-09-24

Family

ID=45530699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002096A BR112013002096A2 (pt) 2010-07-28 2011-07-27 compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas

Country Status (11)

Country Link
US (1) US9217022B2 (https=)
EP (1) EP2598161A4 (https=)
JP (1) JP2013535471A (https=)
KR (1) KR20130101005A (https=)
CN (1) CN103200956A (https=)
AU (1) AU2011282745A1 (https=)
BR (1) BR112013002096A2 (https=)
CA (1) CA2806749A1 (https=)
EA (1) EA201390182A1 (https=)
MX (1) MX2013001131A (https=)
WO (1) WO2012015975A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299425A1 (en) * 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
EP1976873A2 (en) * 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2008112939A2 (en) * 2007-03-13 2008-09-18 Board Of Regents, The University Of Texas System Composition and method for making oligo-benzamide compounds
US8236983B2 (en) * 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
AU2008232709C1 (en) * 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
WO2010120476A2 (en) 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
JP2013532172A (ja) 2010-07-09 2013-08-15 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 安定化したインスリン分泌促進ペプチド及び使用方法

Also Published As

Publication number Publication date
WO2012015975A3 (en) 2012-05-10
KR20130101005A (ko) 2013-09-12
EP2598161A4 (en) 2014-02-19
EP2598161A2 (en) 2013-06-05
EA201390182A1 (ru) 2014-01-30
US9217022B2 (en) 2015-12-22
AU2011282745A1 (en) 2013-03-14
CN103200956A (zh) 2013-07-10
CA2806749A1 (en) 2012-02-02
WO2012015975A2 (en) 2012-02-02
JP2013535471A (ja) 2013-09-12
MX2013001131A (es) 2013-10-17
US20130184203A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
BR112013002096A2 (pt) compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas
HUS2200033I1 (hu) CGRP receptor antagonisták
CY2020010I1 (el) Ενωσεις oi οποιες τροποποιουν τον υποδοχεα ανδρογονου
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
LT2593452T (lt) Heterocikliniai junginiai, kaip ip receptoriaus agonistai
BRPI1015096A2 (pt) agonista de receptor beta de hormônio tireoideano
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
EP2638390A4 (en) MULTIFUNCTIONAL BREATHING ANALYZER
BR112013009935C8 (pt) compostos
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
DK2648516T3 (da) Substituerede pyridinon-pyridinylforbindelser
DK2794626T6 (da) E-selectin-antagonistforbindelser
PT2506716T (pt) Novos compostos tricíclicos
HRP20150167T1 (xx) Spojevi kao antagonisti bradikinina-b1
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI1005525A2 (pt) compostos de azaazuleno
CO6801726A2 (es) Compuestos
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
DK2649070T3 (da) Triazolpyridinforbindelser
UY33156A (es) Nuevos compuestos tienopirrol
BR112012002336A2 (pt) compostos aza-heterocíclicos
BR112014010780A2 (pt) conjugados do peptídeo agonista do receptor glp-1-gastrina
DK2539323T3 (da) Fobindelser som Bradykinin-B1-antagonister

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.